Long Term Evaluation of the Impact of Autologous Peripheral Blood Stem Cell Transplantation in Multiple Myeloma: A Cost-Effectiveness Analysis

Alessandro Corso, Silvia Mangiacavalli, Federica Cocito, Cristiana Pascutto, Virginia Valeria Ferretti, Alessandra Pompa, Roberta Ciampichini, Lara Pochintesta, Lorenzo G. Mantovani

Research output: Contribution to journalArticle

Abstract

Background:High-dose therapy with autologous peripheral stem cell transplantation represents today the standard approach for younger multiple myeloma patients. This study aimed to evaluate the long term economic impact of autologous transplantation with respect to conventional therapy.Methods:We retrospectively reviewed the charts of multiple myeloma patients diagnosed at our department between 1986 and 2003 and treated according to the therapy considered standard at the time of diagnosis. Analysis of costs was done by assessing resource utilization and direct costs were measured and monetized before proceeding with the analysis, based on public health service tariffs.Results:Group A including 78 patients treated with Melphalan and Prednisone was compared with Group B including 74 patients who received an autologous transplant. The median overall survival was 3.2 and 5.4 years respectively (p = 0.0002). Mean cost per patient was significantly higher in group B with respect to group A (102373€ vs 23825€; p

Original languageEnglish
Article numbere75047
JournalPLoS One
Volume8
Issue number9
DOIs
Publication statusPublished - Sep 30 2013

Fingerprint

Peripheral Blood Stem Cell Transplantation
cell transplantation
myeloma
cost effectiveness
Cost effectiveness
blood cells
Stem cells
Multiple Myeloma
Cost-Benefit Analysis
stem cells
Blood
Costs
Melphalan
Costs and Cost Analysis
therapeutics
Autografts
Public health
Prednisone
autografting
prednisone

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Long Term Evaluation of the Impact of Autologous Peripheral Blood Stem Cell Transplantation in Multiple Myeloma : A Cost-Effectiveness Analysis. / Corso, Alessandro; Mangiacavalli, Silvia; Cocito, Federica; Pascutto, Cristiana; Ferretti, Virginia Valeria; Pompa, Alessandra; Ciampichini, Roberta; Pochintesta, Lara; Mantovani, Lorenzo G.

In: PLoS One, Vol. 8, No. 9, e75047, 30.09.2013.

Research output: Contribution to journalArticle

@article{93e9d2b9ce82444ea709b4f67cd15925,
title = "Long Term Evaluation of the Impact of Autologous Peripheral Blood Stem Cell Transplantation in Multiple Myeloma: A Cost-Effectiveness Analysis",
abstract = "Background:High-dose therapy with autologous peripheral stem cell transplantation represents today the standard approach for younger multiple myeloma patients. This study aimed to evaluate the long term economic impact of autologous transplantation with respect to conventional therapy.Methods:We retrospectively reviewed the charts of multiple myeloma patients diagnosed at our department between 1986 and 2003 and treated according to the therapy considered standard at the time of diagnosis. Analysis of costs was done by assessing resource utilization and direct costs were measured and monetized before proceeding with the analysis, based on public health service tariffs.Results:Group A including 78 patients treated with Melphalan and Prednisone was compared with Group B including 74 patients who received an autologous transplant. The median overall survival was 3.2 and 5.4 years respectively (p = 0.0002). Mean cost per patient was significantly higher in group B with respect to group A (102373€ vs 23825€; p",
author = "Alessandro Corso and Silvia Mangiacavalli and Federica Cocito and Cristiana Pascutto and Ferretti, {Virginia Valeria} and Alessandra Pompa and Roberta Ciampichini and Lara Pochintesta and Mantovani, {Lorenzo G.}",
year = "2013",
month = "9",
day = "30",
doi = "10.1371/journal.pone.0075047",
language = "English",
volume = "8",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "9",

}

TY - JOUR

T1 - Long Term Evaluation of the Impact of Autologous Peripheral Blood Stem Cell Transplantation in Multiple Myeloma

T2 - A Cost-Effectiveness Analysis

AU - Corso, Alessandro

AU - Mangiacavalli, Silvia

AU - Cocito, Federica

AU - Pascutto, Cristiana

AU - Ferretti, Virginia Valeria

AU - Pompa, Alessandra

AU - Ciampichini, Roberta

AU - Pochintesta, Lara

AU - Mantovani, Lorenzo G.

PY - 2013/9/30

Y1 - 2013/9/30

N2 - Background:High-dose therapy with autologous peripheral stem cell transplantation represents today the standard approach for younger multiple myeloma patients. This study aimed to evaluate the long term economic impact of autologous transplantation with respect to conventional therapy.Methods:We retrospectively reviewed the charts of multiple myeloma patients diagnosed at our department between 1986 and 2003 and treated according to the therapy considered standard at the time of diagnosis. Analysis of costs was done by assessing resource utilization and direct costs were measured and monetized before proceeding with the analysis, based on public health service tariffs.Results:Group A including 78 patients treated with Melphalan and Prednisone was compared with Group B including 74 patients who received an autologous transplant. The median overall survival was 3.2 and 5.4 years respectively (p = 0.0002). Mean cost per patient was significantly higher in group B with respect to group A (102373€ vs 23825€; p

AB - Background:High-dose therapy with autologous peripheral stem cell transplantation represents today the standard approach for younger multiple myeloma patients. This study aimed to evaluate the long term economic impact of autologous transplantation with respect to conventional therapy.Methods:We retrospectively reviewed the charts of multiple myeloma patients diagnosed at our department between 1986 and 2003 and treated according to the therapy considered standard at the time of diagnosis. Analysis of costs was done by assessing resource utilization and direct costs were measured and monetized before proceeding with the analysis, based on public health service tariffs.Results:Group A including 78 patients treated with Melphalan and Prednisone was compared with Group B including 74 patients who received an autologous transplant. The median overall survival was 3.2 and 5.4 years respectively (p = 0.0002). Mean cost per patient was significantly higher in group B with respect to group A (102373€ vs 23825€; p

UR - http://www.scopus.com/inward/record.url?scp=84884741831&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884741831&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0075047

DO - 10.1371/journal.pone.0075047

M3 - Article

C2 - 24098678

AN - SCOPUS:84884741831

VL - 8

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 9

M1 - e75047

ER -